LT3174875T - (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gavimo būdas ir jo, skirto naudoti kaip aktyvų farmacinį ingredientą, gryninimas - Google Patents
(4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gavimo būdas ir jo, skirto naudoti kaip aktyvų farmacinį ingredientą, gryninimasInfo
- Publication number
- LT3174875T LT3174875T LTEP15742306.2T LT15742306T LT3174875T LT 3174875 T LT3174875 T LT 3174875T LT 15742306 T LT15742306 T LT 15742306T LT 3174875 T LT3174875 T LT 3174875T
- Authority
- LT
- Lithuania
- Prior art keywords
- methoxifenyl
- naphthiridine
- carboxamide
- dihydro
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179544 | 2014-08-01 | ||
| PCT/EP2015/067340 WO2016016287A1 (de) | 2014-08-01 | 2015-07-29 | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3174875T true LT3174875T (lt) | 2020-11-25 |
Family
ID=51260727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15742306.2T LT3174875T (lt) | 2014-08-01 | 2015-07-29 | (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gavimo būdas ir jo, skirto naudoti kaip aktyvų farmacinį ingredientą, gryninimas |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | USRE49575E1 (en:Method) |
| EP (2) | EP3174875B1 (en:Method) |
| JP (1) | JP6818674B2 (en:Method) |
| KR (3) | KR20250108757A (en:Method) |
| CN (4) | CN116655629A (en:Method) |
| AR (1) | AR101403A1 (en:Method) |
| AU (1) | AU2015295376C1 (en:Method) |
| BR (1) | BR112017001678B1 (en:Method) |
| CA (2) | CA3146285C (en:Method) |
| CL (1) | CL2017000263A1 (en:Method) |
| CO (1) | CO2017000886A2 (en:Method) |
| DK (1) | DK3174875T3 (en:Method) |
| ES (1) | ES2828704T3 (en:Method) |
| HR (1) | HRP20201800T1 (en:Method) |
| HU (1) | HUE051350T2 (en:Method) |
| IL (1) | IL250239B (en:Method) |
| JO (1) | JO3648B1 (en:Method) |
| LT (1) | LT3174875T (en:Method) |
| MX (1) | MX369467B (en:Method) |
| MY (1) | MY198066A (en:Method) |
| PE (1) | PE20170141A1 (en:Method) |
| PL (1) | PL3174875T3 (en:Method) |
| PT (1) | PT3174875T (en:Method) |
| RS (1) | RS60921B1 (en:Method) |
| RU (1) | RU2729998C9 (en:Method) |
| SG (1) | SG11201700785UA (en:Method) |
| SI (1) | SI3174875T1 (en:Method) |
| TW (1) | TWI684593B (en:Method) |
| UA (1) | UA122773C2 (en:Method) |
| UY (2) | UY36251A (en:Method) |
| WO (1) | WO2016016287A1 (en:Method) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2729998C9 (ru) * | 2014-08-01 | 2020-10-20 | Байер Фарма Акциенгезельшафт | Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и его очистки для применения в качестве фармацевтического активного ингредиента |
| KR102669559B1 (ko) * | 2015-08-21 | 2024-05-28 | 바이엘 파마 악티엔게젤샤프트 | (4s)-4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복스아미드의 제조 방법 및 활성 제약 성분으로서 사용하기 위한 그의 정제 |
| EP3560922A1 (de) | 2018-04-24 | 2019-10-30 | Bayer Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester |
| JOP20210242A1 (ar) | 2019-03-05 | 2023-01-30 | Bayer Ag | تصنيع 4-أمينو-5-مثيل-1h- بيريدين-2(1h)-ون (مركب وسيط لتصنيع فينيرينون مضاد لـ mr) من أكسيد-2-كلورو-5-مثيل-4-نيترو-بيريدين-1 باستخدام المركب الوسيط 2-كلورو-5-مثيل-4-بيريدين أمين |
| CN113412255B (zh) | 2019-03-05 | 2024-07-02 | 拜耳公司 | 制备4-氨基-5-甲基吡啶酮的方法 |
| KR20220084104A (ko) * | 2019-10-17 | 2022-06-21 | 바이엘 악티엔게젤샤프트 | (4r,4s)-4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복스아미드를 제조하기 위한 광화학 방법 |
| PE20221415A1 (es) * | 2019-10-17 | 2022-09-20 | Bayer Ag | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxi-fenil)-5-hidroxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo por separacion de racematos por medio de ester de acido tartarico diastereoisomero |
| JOP20220148A1 (ar) * | 2019-10-17 | 2023-01-30 | Bayer Ag | عملية لانتاج استرات أسيلوكسي مثيل من حمض (4s)- (4-سيانو-2-ميثوكسي فنيل)-5-ايثوكسي-2، 8-ثنائي مثيل-1، 4-ثنائي هيدرو-1، 6-نفثيريدين-3-كربوكسيليك |
| CN114698375B (zh) * | 2019-10-17 | 2024-08-02 | 拜耳公司 | 制备2-氰基乙基(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-羧酸酯的方法 |
| EP3900722A1 (en) | 2020-04-22 | 2021-10-27 | Bayer AG | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
| EP4138826A1 (en) | 2020-04-22 | 2023-03-01 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| TW202214624A (zh) | 2020-06-16 | 2022-04-16 | 德商拜耳廠股份有限公司 | 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法 |
| CN112237573B (zh) * | 2020-10-29 | 2023-12-22 | 瑞阳制药股份有限公司 | 含finerenone的片剂及其制备方法 |
| WO2022214206A1 (en) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
| CN114149427A (zh) * | 2021-12-18 | 2022-03-08 | 上海鼎雅药物化学科技有限公司 | 非奈利酮及其中间体的合成方法 |
| CN115340539B (zh) | 2022-01-19 | 2024-02-27 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
| CN115340540A (zh) * | 2022-01-20 | 2022-11-15 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
| CN114524812A (zh) * | 2022-03-18 | 2022-05-24 | 湖南凯铂生物药业有限公司 | 1,4-二氢-1,6-萘啶化合物的晶型制备以及合成方法 |
| WO2023205164A1 (en) | 2022-04-18 | 2023-10-26 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of finerenone |
| EP4286368A1 (de) | 2022-05-31 | 2023-12-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril |
| WO2024075139A1 (en) * | 2022-10-06 | 2024-04-11 | Maithri Drugs Private Limited | A process for preparation of finerenone and intermediates thereof |
| JP2025537211A (ja) | 2022-11-04 | 2025-11-14 | ナンジン ブイケア ファーマテック カンパニー リミテッド | ジアステレオマー酒石酸エステルによりラセミ体を分割することによりフィネレノンを調製する方法 |
| KR20250105629A (ko) * | 2022-11-23 | 2025-07-08 | 바이엘 악티엔게젤샤프트 | 유형 i 당뇨병에서의 만성 신장 질환의 치료 |
| AU2023392150A1 (en) | 2022-12-16 | 2025-05-29 | Bayer Aktiengesellschaft | Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
| WO2024147053A1 (en) * | 2023-01-03 | 2024-07-11 | Optimus Drugs Pvt Ltd | Improved process for the preparation of finerenone |
| EP4682147A1 (en) * | 2023-03-17 | 2026-01-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor |
| WO2025104752A1 (en) * | 2023-11-18 | 2025-05-22 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of (4s)4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
| CN120081840A (zh) * | 2023-12-01 | 2025-06-03 | 山东诚创蓝海医药科技有限公司 | 一种非奈利酮-马来酸共晶及其制备方法 |
| IT202300027735A1 (it) | 2023-12-22 | 2025-06-22 | Ind Chimica S R L | Processo per la preparazione di (4s)-4-(4-ciano-2-metossifenil)-5-etossi-1,4-diidro-2,8-dimetil-1,6-naftiridina-3-carbossammide |
| EP4691463A1 (en) | 2024-08-05 | 2026-02-11 | Bayer Aktiengesellschaft | Finerenone for use in a method of preventing or treating heart failure in a patient receiving a cyp3a4 inhibitor or a cyp3a4 inducer |
| US20250313559A1 (en) | 2024-01-05 | 2025-10-09 | Bayer Aktiengesellschaft | Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
| WO2025247801A1 (en) * | 2024-05-30 | 2025-12-04 | Bayer Aktiengesellschaft | Determination of a dosage of a nonsteroidal mineralocorticoid receptor antagonist |
| CN119462643A (zh) * | 2024-10-17 | 2025-02-18 | 河北国龙制药有限公司 | 一种非奈利酮单晶及其制备方法和应用 |
| CN119019395A (zh) * | 2024-10-29 | 2024-11-26 | 成都诺和晟欣生物医药有限公司 | 一种非奈利酮晶型ⅰ的制备方法 |
| CN119684289A (zh) * | 2024-12-18 | 2025-03-25 | 安徽先和医药研究有限公司 | 一种非奈利酮的制备方法 |
| CN119684288A (zh) * | 2024-12-18 | 2025-03-25 | 安徽先和医药研究有限公司 | 非奈利酮的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL75987A (en) * | 1984-08-25 | 1991-07-18 | Goedecke Ag | Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them |
| US4895860A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corporation | Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9914825D0 (en) | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2008516978A (ja) * | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用 |
| CN101115726A (zh) * | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| AU2006201739A1 (en) * | 2005-05-05 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles |
| US20080312209A1 (en) | 2005-07-12 | 2008-12-18 | Glaxo Group Limited | Piperazine Heteroaryl Derivatives as Gpr38 Agonists |
| DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
| DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
| DE102007009494A1 (de) * | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| CN102020587A (zh) | 2010-11-25 | 2011-04-20 | 大连凯飞精细化工有限公司 | 2-甲氧基-4-氰基苯甲醛的合成方法 |
| RU2729998C9 (ru) * | 2014-08-01 | 2020-10-20 | Байер Фарма Акциенгезельшафт | Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и его очистки для применения в качестве фармацевтического активного ингредиента |
-
2015
- 2015-07-29 RU RU2017106602A patent/RU2729998C9/ru active
- 2015-07-29 MX MX2017001507A patent/MX369467B/es active IP Right Grant
- 2015-07-29 PE PE2017000143A patent/PE20170141A1/es unknown
- 2015-07-29 BR BR112017001678-8A patent/BR112017001678B1/pt active IP Right Grant
- 2015-07-29 CA CA3146285A patent/CA3146285C/en active Active
- 2015-07-29 LT LTEP15742306.2T patent/LT3174875T/lt unknown
- 2015-07-29 US US17/002,115 patent/USRE49575E1/en active Active
- 2015-07-29 RS RS20201213A patent/RS60921B1/sr unknown
- 2015-07-29 PT PT157423062T patent/PT3174875T/pt unknown
- 2015-07-29 CA CA2956529A patent/CA2956529A1/en active Pending
- 2015-07-29 JP JP2017505480A patent/JP6818674B2/ja active Active
- 2015-07-29 HR HRP20201800TT patent/HRP20201800T1/hr unknown
- 2015-07-29 PL PL15742306T patent/PL3174875T3/pl unknown
- 2015-07-29 HU HUE15742306A patent/HUE051350T2/hu unknown
- 2015-07-29 UA UAA201701875A patent/UA122773C2/uk unknown
- 2015-07-29 SI SI201531406T patent/SI3174875T1/sl unknown
- 2015-07-29 CN CN202310619597.7A patent/CN116655629A/zh active Pending
- 2015-07-29 MY MYPI2017700334A patent/MY198066A/en unknown
- 2015-07-29 CN CN201580053456.7A patent/CN106795155B/zh active Active
- 2015-07-29 WO PCT/EP2015/067340 patent/WO2016016287A1/de not_active Ceased
- 2015-07-29 KR KR1020257022052A patent/KR20250108757A/ko active Pending
- 2015-07-29 CN CN202310616268.7A patent/CN116655627A/zh active Pending
- 2015-07-29 CN CN202310620718.XA patent/CN116655630B/zh active Active
- 2015-07-29 ES ES15742306T patent/ES2828704T3/es active Active
- 2015-07-29 KR KR1020177005278A patent/KR102527893B1/ko active Active
- 2015-07-29 AU AU2015295376A patent/AU2015295376C1/en active Active
- 2015-07-29 US US15/329,043 patent/US10059707B2/en not_active Ceased
- 2015-07-29 SG SG11201700785UA patent/SG11201700785UA/en unknown
- 2015-07-29 KR KR1020237014295A patent/KR102830206B1/ko active Active
- 2015-07-29 DK DK15742306.2T patent/DK3174875T3/da active
- 2015-07-29 EP EP15742306.2A patent/EP3174875B1/de active Active
- 2015-07-29 EP EP19213735.4A patent/EP3660015A1/de not_active Withdrawn
- 2015-07-30 JO JOP/2015/0184A patent/JO3648B1/ar active
- 2015-07-30 TW TW104124689A patent/TWI684593B/zh active
- 2015-07-31 AR ARP150102475A patent/AR101403A1/es unknown
- 2015-07-31 UY UY0001036251A patent/UY36251A/es not_active Application Discontinuation
-
2017
- 2017-01-23 IL IL250239A patent/IL250239B/en active IP Right Grant
- 2017-01-31 CL CL2017000263A patent/CL2017000263A1/es unknown
- 2017-01-31 CO CONC2017/0000886A patent/CO2017000886A2/es unknown
-
2018
- 2018-08-27 US US16/114,198 patent/US10399977B2/en not_active Ceased
-
2020
- 2020-11-03 US US17/087,659 patent/USRE49860E1/en active Active
-
2023
- 2023-04-28 UY UY0001040247A patent/UY40247A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3174875T (lt) | (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gavimo būdas ir jo, skirto naudoti kaip aktyvų farmacinį ingredientą, gryninimas | |
| FR22C1058I2 (fr) | Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide | |
| ZA201801859B (en) | Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | |
| IL256392A (en) | Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b | |
| BR112016016158A2 (pt) | Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| IL254098B (en) | Compressed ring derivatives and method of preparation, intermediates, pharmaceutical preparations and their use | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| IL252418B (en) | Envenomation therapies and related pharmaceutical compositions, systems and kits | |
| LT3262037T (lt) | Naujas chinolino darinys, skirtas panaudoti virusinių infekcijų gydymui ir prevencijai | |
| LT3399978T (lt) | Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas | |
| LT3261642T (lt) | Chinolino dariniai, skirti naudoti virusinės infekcijos gydymui arba prevencijai | |
| ZA201802033B (en) | Heteroaryl compounds and their use as therapeutic drugs | |
| EP3299016A4 (en) | USE OF OXIRACETAM DEXTROGYRE IN THE PHARMACEUTICAL FIELD | |
| BR112016026552A2 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| DK3185867T3 (da) | Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| LT3326463T (lt) | Preparatas erkėms ir jo, kaip biologinės kovos priemonės, naudojimas | |
| BR112015005627A2 (pt) | composto, composição farmacêutica, uso de composto, método de tratamento e invenção. | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| IL248578A0 (en) | Quinzoline derivatives, pharmaceutical compounds containing them and their uses | |
| ZA201801865B (en) | Method for the preparation of the metabolites of (4s)- and (4r)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and the use thereof | |
| DK3842436T3 (da) | Farmaceutisk sammensætning omfattende imidazopyridin- eller imidazotriazinderivater til anvendelse i behandlingen af skizofreni | |
| LT3383402T (lt) | Farmacinė kompozicija, apimanti darunavirą, ir jos gamybos būdas | |
| BR112016020135A2 (pt) | mistura de composto, seus usos, composição farmacêutica, e conjunto (kit) |